# Knight Therapeutics

Knight Therapeutics is a Corporate Investor based in Montreal, Canada.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Montreal, Canada
- **Region:** North America
- **Address:** 3400 De Maisonneuve Blvd. W., Suite 1055, Montreal, Québec H3Z 3B8, Canada
- **Founded:** 2014
- **Assets under management:** Undisclosed
- **Website:** knighttx.com
- **LinkedIn:** https://www.linkedin.com/company/knight-therapeutics
- **Wikidata:** Q48743359

## Regulatory record

- **Reports private funds:** No

## About

Knight Therapeutics was founded in 2014 by Jonathan Ross Goodman, the former CEO of Paladin Labs, following Paladin's acquisition by Endo International. The Goodman family's pharmaceutical roots run deep: Jonathan's father, Morris Goodman, built Pharmascience Inc., a generic drug manufacturer now led by his brother David. Knight emerged not as a de novo startup but as a vehicle seeded with Paladin's legacy cash and a royalty portfolio, giving it a balance sheet from day one rather than a venture fund's run-and-gun mandate. Knight operates in two distinct gears. The first is an operating business that licenses and commercializes specialty pharmaceuticals, consumer health products, and medical devices in Canada and select Latin American markets. The second is a strategic investment portfolio spanning equity positions in other pharma companies, limited partner commitments to sector-focused funds, and a structured loan book that often takes royalty interests as collateral. Confirmed historical and active positions include equity stakes in Medison Pharma, a Canadian-Israeli commercial partner, and loans secured against future product royalties, a structure that provides downside protection through priority claims on approved-drug cash flows. Team size is not publicly disclosed, though the firm lists its headquarters at 3400 De Maisonneuve Blvd. West in Montreal. CEO Samira Sakhia, Paladin's former CFO, took the top operating role, while Chairman James C. Gale, a founding partner at Signet Healthcare Partners, anchors the board's investment-committee function. Adjacent to Knight, Goodman maintains Long Zone Holdings, a personal investment vehicle that occasionally co-invests alongside the corporate balance sheet. The Morris and Rosalind Goodman Family Foundation channels philanthropic capital, primarily into Montreal healthcare and Jewish community causes. What distinguishes Knight from a generic specialty pharma company is its permanent capital base. Knight has no venture fund sunset clauses and no LP redemption pressure — it deploys corporate cash and royalty income with an investing horizon that can wait for drug-approval timelines. This architecture effectively turns a public-company treasury into a patient, theme-concentrated allocator that competes with venture debt funds and crossover biotech investors on their own turf.

## Sectors

- Pharmaceuticals
- Consumer Health
- Medical Devices

## People

- Jonathan Ross Goodman — Founder and Executive Chairman
- Samira Sakhia — President and CEO
- James C. Gale — Chairman of the Board

## Questions

### Who runs investment decisions at Knight Therapeutics?

Investment decisions flow through the senior leadership team, with Jonathan Ross Goodman as Executive Chairman and Samira Sakhia as President and CEO. James C. Gale, the Board Chairman and a founding partner of Signet Healthcare Partners, brings additional investment-committee experience from the life-sciences venture world. The board-level review structure reflects Knight's hybrid nature: it evaluates drug licensing deals, equity stakes, and structured credit instruments under one roof.

### How does Knight's dual operating-and-investing model actually work?

Knight runs a specialty pharma operating business that generates cash from drug commercialization in Canada and Latin America, then recycles that cash into three types of investment: equity stakes in other pharma and biotech companies, limited partner commitments to external life-sciences funds, and royalty-backed loans where Knight earns interest plus a share of future product revenue. The royalty loan book functions like secured credit with upside participation, distinct from the mezzanine or venture debt most biotech firms encounter.

### Does Knight participate in fund commitments or only direct deals?

Knight does both. Its strategic fund investment portfolio includes LP commitments to third-party life-sciences and healthcare funds globally, while its strategic loan portfolio and equity book represent direct exposure. The firm's regulatory filings and public disclosures historically reference a mix of direct pharmaceutical equity positions, limited partnership interests in sector funds, and royalty-backed credit instruments.

### What is the relationship between Knight Therapeutics and Pharmascience?

Pharmascience Inc. is a privately held generic drug manufacturer founded by Morris Goodman, Jonathan Goodman's father. Jonathan's brother David Goodman leads Pharmascience. The two companies are operationally distinct — Pharmascience focuses on generics manufacturing, while Knight pursues branded specialty pharma and strategic investment — but they share a common Goodman-family pharmaceutical legacy in Montreal.

## Related profiles

- [Knight Frank Staff Pension Fund](https://altss.com/profile/knight-frank-staff-pension-fund)
- [Knights of Columbus](https://altss.com/profile/knights-of-columbus)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/knight-therapeutics

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology